Despite the excellent results of treatment of Type I lobar pneumonia with antipneumococcus serum which have been reported by Cole,1 no final agreement as to the value of the procedure has been reached by clinicians. Approximately 1,000 treated cases are now on record in the literature.2 They have been reported, for the most part, in small groups, and the mortality rates have varied from 0 to 27 per cent. Each observer is naturally influenced by his own series, and, in fact, in certain quarters skepticism seems to exist as to the real value of the serum.
It is obvious that with the criterion of success which has hitherto been relied on, namely, the degree of reduction in the gross mortality of treated Type I infections, a huge number of cases will have to be collected before the matter will be settled to the satisfaction of every one. At
BLOOMFIELD AL. THE THERAPEUTIC VALUE OF TYPE I ANTIPNEUMOCOCCUS SERUM. JAMA. 1923;81(17):1437–1438. doi:10.1001/jama.1923.02650170035013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: